Skip to main content

Table 6 Secondary analysis - Logistic regression and diagnostic accuracy results of biochemical liver function tests and non-invasive ICG clearance test at pre-RYGB for predicting significant fatty livera at pre-RYGB time point

From: Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery

Test At pre-RYGB Odds ratio AUCb
Number (99.4% CI) P (99.4% CI)
AST, U/L 101 1.09 (1.01, 1.17) 0.001 0.72 (0.61, 0.82)
ALT, U/L 101 1.07 (1.01, 1.12) <0.001 0.76 (0.66, 0.85)
ALK, U/L 101 0.98 (0.95, 1.01) 0.03 0.65 (0.53, 0.77)
Total bilirubin, mg/dL 101 1.20 (0.32, 4.48) 0.70 0.53 (0.41, 0.64)
PT, second 98 1.57 (0.57, 4.34) 0.22 0.54 (0.41, 0.67)
PTT, second 36 0.96 (0.83, 1.10) 0.37 0.46 (0.26, 0.66)
ICG k value 100 0.86 (0.27, 2.72) 0.71 0.53 (0.41, 0.66)
  1. AST Aspartate transaminase, ALT Alanine transaminase, ALK alkaline phosphatase, ICG Indocyanine green, PT Prothrombin time, PTT Partial Thromboplastin Time, RYGB Roux-en-Y gastric bypass
  2. aThe gold standard histological diagnosis for significant fatty liver, including nonalcoholic steatohepatitis (NASH) and NASH plus fibrosis, is defined as steatosis >5% with at least a few balloon cells and lobular inflammation >2 foci/200×
  3. The significance criterion was P < 0.006 (i.e., 0.05/8, Bonferroni correction)
  4. bArea under the receiver operating characteristic curve, which is a good measure of diagnostic accuracy ranging from 0.50 (chance) to 1.0 (perfect prediction)